Echo Biotech is an innovative biotech company dedicated to the development and clinical translation of exosome technologies. The company has built three core technology platforms: Exoomics®, a multi-omics platform for exosome research; Echosome®, an engineered exosome platform; and Echopharm®, a platform for large-scale exosome manufacturing. With these integrated capabilities, Echo Biotech has established collaborations with more than 2,000 institutions worldwide, contributed to over 300 scientific publications, and supported research involving more than 100 sample types and 80,000+ samples.

Echo Biotech has been recognized as a national-level specialized and sophisticated “Little Giant” enterprise and a National High-Tech Enterprise, and has established a postdoctoral research workstation. The company has also completed multiple rounds of financing, with total funding reaching several hundred million RMB.

Its foundational work in engineered exosome technology has been published in the Journal of Extracellular Vesicles, one of the leading journals in the field. Echo Biotech’s human mesenchymal stem cell-derived exosome raw material product, GoldenExo®, has achieved dual international filings, including a U.S. FDA Type II Drug Master File (DMF) filing and INCI registration for cosmetic ingredients. In late 2024, the company also participated in the national key R&D program under the “Stem Cell Research and Organ Repair” initiative, contributing to the establishment of quality standards for exosome therapeutics.

Driven by innovation and guided by rigorous quality standards, Echo Biotech is committed to delivering exosome-based solutions for regenerative medicine and systemic anti-aging, and to advancing the future of healthcare through cutting-edge biotechnology.

Beijing Echo Biotech Co., Ltd.

Org chart

Teams

Offices

Beijing Echo Biotech Co., Ltd.

Org chart

Teams

Offices

Related companies